ArticleScientific reports2016
Identifying protective Streptococcus pyogenes vaccine antigens recognized by both B and T cells in human adults and children.
Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- HLA-II peptide-binding diversity shapes humoral immune responses and susceptibility to infections.Nature communications · 2026Article
- The Slr protein of Streptococcus pyogenes is selectively expressed in vivo and is a target for protective antibodies.EMBO molecular medicine · 2026Article
- Identification of immunostimulatory antigens in Group AProceedings of the National Academy of Sciences of the United States of America · 2026Article
- Rational selection of antigenic targets for Group A Streptococcus vaccine: updates, challenges and opportunities.NPJ vaccines · 2026Review
- Conserved molecular chaperone PrsA stimulates protective immunity against group A Streptococcus.NPJ vaccines · 2024Article
- Article
- New modular platform based on multi-adjuvanted amphiphilic chitosan nanoparticles for efficient lipopeptide vaccine delivery against group A streptococcus.Asian journal of pharmaceutical sciences · 2022Article
- Immunization with the lipoprotein FtsB stimulates protective immunity againstFrontiers in microbiology · 2022Article
- Overcoming Symmetry Mismatch in Vaccine Nanoassembly through Spontaneous Amidation.Angewandte Chemie (Weinheim an der Bergstrasse, Germany) · 2021Article
- Overcoming Symmetry Mismatch in Vaccine Nanoassembly through Spontaneous Amidation.Angewandte Chemie (International ed. in English) · 2021Article
- A general approach for predicting protein epitopes targeted by antibody repertoires using whole proteomes.PloS one · 2019Article
- Peptide Arrays: Development and Application.Analytical chemistry · 2018Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
No commercial vaccine exists against Group A streptococci (GAS; Streptococcus pyogenes) and only little is known about anti-GAS protective immunity. In our effort to discover new protective vaccine candidates, we selected 21 antigens based on an in silico evaluation. These were all well-conserved among different GAS strains, upregulated in host-pathogen interaction studies, and predicted to be extracellular or associated with the surface of the bacteria. The antigens were tested for both antibody recognition and T cell responses in human adults and children. The antigenicity of a selected group of antigens was further validated using a high-density peptide array technology that also identified the linear epitopes. Based on immunological recognition, four targets were selected and tested for protective capabilities in an experimental GAS infection model in mice. Shown for the first time, three of these targets (spy0469, spy1228 and spy1801) conferred significant protection whereas one (spy1643) did not.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.